nach oben

Clinical and Translational Oncology

Erschienen in:

03.08.2020 | Brief Research Article

Regional deep hyperthermia in combination with whole brain radiotherapy (WBRT) in poor prognosis patients with brain metastases

verfasst von: M. Lloret, L. García-Cabrera, M. Zajac, P. C. Lara

Erschienen in: Clinical and Translational Oncology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study is to assess for the first time, the role of regional deep hyperthermia in combination with radiotherapy and systemic therapy in patients with poor prognosis of brain metastases (GPI ≤ 2.5).

Methods

Patients with confirmed cerebral metastases and classified as GPI score ≤ 2.5 were included in this prospective study. Pretreatment stratification was defined as patients with 0–1 GPI score (Group A) and patients with 1.5–2.5 GPI score (Group B). HT was applied twice a week, 60 min per session, during RT by regional capacitive device (HY-DEEP 600WM system) at 13.56 MHz radiofrequency.

Results

Between June 2015 and June 2017, 15 patients and a total of 49 brain metastases were included in the protocol. All patients received all HT sessions as planned. RT and systemic therapy were also completed as prescribed. Tolerance to treatment was excellent and no toxicity was registered. Patients with HT effective treatment time longer than the median (W90time > 88%) showed better actuarial PFS at 6 and 12 months (100% and 66.7%, respectively) compared to those with less HT effective treatment time (50% and 0%, respectively) (p < 0.031). Median OS was 6 months (range 1–36 months). Stratification by GPI score showed a median OS of 3 months (CI 95% 2.49–3.51) in Group A and 8.0 months (CI 95% 5.15–10.41) in Group B (p = 0.035).

Conclusions

Regional hyperthermia is a feasible and safe technique to be used in combination with RT in brain metastases patients, improving PFS and survival in poor prognostic brain metastasis patients.

Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48–544. https://doi.org/10.1007/s11912-011-0203-y.CrossRefPubMed

Nieder C, Mehta MP. Prognostic indices for brain metastases–usefulness and challenges. Radiat Oncol. 2009;4(4):10. https://doi.org/10.1186/1748-717X-4-10.CrossRefPubMedPubMedCentral

Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655–61. https://doi.org/10.1016/j.ijrobp.2009.08.025.CrossRefPubMed

Crezee H, van Leeuwen CM, Oei AL, et al. Thermoradiotherapy planning: Integration in routine clinical practice. Int J Hyperth. 2015;32(1):41–9. https://doi.org/10.3109/02656736.2015.1110757.CrossRef

Dewhirst MW, Vujaskovic Z, Jones E, et al. Re-setting the biologic rationale for thermal therapy. Int J Hyperth. 2005;21(8):779–90. https://doi.org/10.1080/02656730500271668.CrossRef

Peeken JC, Vaupel P, Combs SE. Integrating hyperthermia into modern radiation oncology: what evidence is necessary? Front Oncol. 2017;7:132. https://doi.org/10.3389/fonc.2017.00132.CrossRefPubMedPubMedCentral

Vernon CC, Hand JW, Field SB, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from ve randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys. 1996;35(4):731–44. https://doi.org/10.1016/0360-3016(96)00154-X.CrossRefPubMed

van der Zee J, González González D, van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet. 2000;355(9210):1119–25. https://doi.org/10.1016/S0140-6736(00)02059-6.CrossRefPubMed

Kang M, Liu WQ, Qin YT, et al. Long-term efficacy of microwave hyperthermia combined with chemoradiotherapy in treatment of nasopharyngeal carcinoma with cervical lymph node metastases. Asian Pac J Cancer Prev. 2013;14(12):7395–400. https://doi.org/10.7314/APJCP.2013.14.12.7395.CrossRefPubMed

10.

De Haas-Kock DFM, Buijsen J, Pijls-Johannesma M, et al. Concomitant hyperthermia and radiation therapy for treating locally advanced rectal cancer. Cochrane Database Syst Rev. 2009;3:CD006269. https://doi.org/10.1002/14651858.CD006269.CrossRef

11.

Datta NR, Puric E, Klingbiel D, et al. Hyperthermia and radiation therapy in locoregional recurrent breast cancers: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2016;94(5):1073–87. https://doi.org/10.1016/j.ijrobp.2015.12.361.CrossRefPubMed

12.

Lutgens LCHW, Koper PCM, Jobsen JJ, et al. Radiation therapy combined with hyperthermia versus cisplatin for locally advanced cervical cancer: results of the randomized RADCHOC trial. Radiother Oncol. 2016;120(3):378–82. https://doi.org/10.1016/j.radonc.2016.02.010.CrossRefPubMed

13.

Byun YH, Gwak HS, Kwon JI, et al. Local recurrence of brain metastasis reduced by intra-operative hyperthermia treatment. Int J Hyperth. 2018;35(1):168–75. https://doi.org/10.1080/02656736.2018.148800.CrossRef

14.

Lloret M, García-Cabrera L, Hernandez A, et al. Feasibility of a deep hyperthermia and radiotherapy programme for advanced tumors: first Spanish experience. Clin Transl Oncol. 2019. https://doi.org/10.1007/s12094-019-02097-9.CrossRefPubMed

15.

Sahinbas H, Rosch M, Demiray M. Temperature measurements in a capacitive system of deep loco-regional hyperthermia. Electromagn Biol Med. 2017;36(3):248–58. https://doi.org/10.1080/15368378.2017.1307221.CrossRefPubMed

16.

Bruggmoser G, Bauchowitz S, Canters R, et al. Quality assurance for clinical studies in regional deep hyperthermia. Strahlenther Onkol. 2011;187(10):605–10. https://doi.org/10.1007/s00066-011-1145-x.CrossRefPubMed

Titel: Regional deep hyperthermia in combination with whole brain radiotherapy (WBRT) in poor prognosis patients with brain metastases
verfasst von: M. Lloret
L. García-Cabrera
M. Zajac
P. C. Lara
Publikationsdatum: 03.08.2020
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 1/2021
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-020-02404-9

Prognostic value of neutrophil–lymphocyte ratio in critically ill patients with cancer: a propensity score matching study

Research Article

Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?

Research Article

Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells

Open Access
Research Article

Positioning error analysis of the fraxion localization system in the intracranial stereotactic radiotherapy of tumors

Research Article

Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study

Research Article

Electronic nicotine delivery systems (ECs) and COVID-19: the perfect storm for young consumers

Zur Zeit gratis
COVID-19
Review Article

Neu im Fachgebiet Onkologie

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

20.01.2025
Risikofaktoren für Krebserkrankungen
Nachrichten

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

16.01.2025
Künstliche Intelligenz im Gesundheitswesen
Nachrichten

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

16.01.2025
Zöliakie
Nachrichten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

15.01.2025
Urothelkarzinom
Nachrichten

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Regional deep hyperthermia in combination with whole brain radiotherapy (WBRT) in poor prognosis patients with brain metastases